Showing results (131-140 of 861) with videos related to
Sort By:
Pageof 87
Developmental Cell|February 18, 2010
Chromatin modifiers, cognitive disorders, and imprinted genesMelissa D Cunningham, Judith A Kassis, Karl PfeiferBiology Letters|June 2, 2017
Climate and sex ratio variation in a viviparous lizardGeorge D Cunningham, Geoffrey M While, Erik WapstraOtolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|October 31, 2007
External auditory canal closure: an alternative management for the refractory chronically draining earNaohiro Yoshida, Calhoun D Cunningham, John T McElveenBritish Journal of Cancer|April 26, 2012
Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resectionA Dewdney, D Cunningham, Y Barbachano, et al.Current Opinion in Structural Biology|January 8, 2017
Peptides and peptidomimetics as regulators of protein-protein interactionsAnna D Cunningham, Nir Qvit, Daria Mochly-RosenDalton Transactions (Cambridge, England : 2003)|June 28, 2012
Pre-steady state reactivity of 5,10,15,20-tetrakis(pentafluorophenyl)-21H,23H-porphyrin iron(III) chloride with hydrogen peroxideIan D Cunningham, Amal Basaleh, Hanaa A GazzazRehabilitation Psychology|July 22, 2009
Parenting and social functioning of children with and without cerebral palsySean D Cunningham, Seth Warschausky, Pamela Dixon ThomasJournal of Family Issues|June 1, 1989
The work motivations of mothers with preschool childrenS Cotton, J K Antill, J D CunninghamEuropean Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancerD C Farrugia, A R Norman, D CunninghamBritish Journal of Cancer|January 24, 2007
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatmentN Starling, D Tilden, J White, et al.Pageof 87